Evidence map›Paper›PMID 33485406›Full record

ArticleThe Lancet. Respiratory medicine2021

α1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action.

Chengliang Yang, Kenneth R Chapman, Aaron Wong, Mingyao Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Respiratory medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. COVID-19 in Individuals with Severe Alpha 1-Antitrypsin Deficiency.International journal of chronic obstructive pulmonary disease · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chengliang YangLatner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Kenneth R ChapmanInstitute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Division of Respiratory Medicine, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Aaron WongLatner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada.
Mingyao LiuLatner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Division of Respiratory Medicine, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada; Department of Physiology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 1L7, Canada. Electronic address: mingyao.liu@utoronto.ca.

Funding

CIHR PJT-148847
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

alpha 1-Antitrypsinalpha 1-Antitrypsin DeficiencyClinical Trials as TopicComorbidityCOVID-19COVID-19 Drug TreatmentGenetic Predisposition to DiseaseHumansMutationRisk FactorsSARS-CoV-2Serine EndopeptidasesSerine Proteinase InhibitorsSeverity of Illness IndexVirus Internalizationalpha 1-AntitrypsinSerine EndopeptidasesSerine Proteinase InhibitorsSERPINA1 protein, humanTMPRSS2 protein, human

Identifiers

PMID33485406
PMCPMC7826115

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.